Highland Therapeutics Announces New Chief Commercial Officer and Appointment of Chief Scientific Officer – Press Release

TORONTO–(Business Wire)–Highland Therapeutics Inc. (“Highland”) today announced two executive appointments at its wholly owned subsidiaries. Mr. Danny Villeneuve has assumed the role of Executive Vice President and Chief Commercial Officer and Dr. Bev Incledon has been promoted to the role of Executive Vice President and Chief Scientific Officer at Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc., respectively. Both appointments are effective immediately.

“I am delighted to welcome Danny to the Ironshore family of companies and congratulate both him and Bev on the appointments,” said David Lickrish, Highland’s Chairman & Chief Executive Officer. “Danny brings a wealth of experience to Ironshore, gained from a 25-year career in the pharmaceutical industry, including 13 years directly in ADHD. His leadership skills and deep expertise in all facets of commercial operations, including sales, marketing and market access will be terrific assets to leverage as we seek to improve outcomes for patients with

Read More

Orthopaedic Research UK and Embryo Ventures Launch Novara Therapeutics to Accelerate Commercialisation of Pioneering Medical Technology

Joint Venture Company Novara Therapeutics is set to advance diagnosis and treatment of bone fractures through a patented bone-targeting contrast agent.

Orthopaedic Research UK (ORUK) and Embryo Ventures (Embryo) announce the formation of Novara Therapeutics, a joint venture company, to commercialise a patented bone-targeting contrast agent. Novara Therapeutics will focus on pre-clinical development of the proprietary imaging and therapeutic technology to advance diagnosis and treatment of bone disease in patients.

Osteoporosis is the most common bone disease, affecting over 200 million people worldwide1. The condition is characterised by a progressive reduction in bone mass and strength that results in more than 8.9 million osteoporotic fracture annually1. With one in three women and one in five men aged over 50 years experiencing an osteoporotic fracture in their lifetime, the condition poses a major public health challenge that is expected to increase markedly as the world’s ageing population

Read More